key: cord-0710664-u59v5v06 authors: Stiles, Deborah F.; Ruotolo, Brenda L.; Kim, Helen; Cho, Jane; Appelbaum, Paul S.; Green, Nancy S. title: Managing Human Subjects Research During a Global Pandemic at an Academic Center: Lessons Learned From COVID-19 date: 2021-12-28 journal: Acad Med DOI: 10.1097/acm.0000000000004426 sha: 56f64a1bca314681c959d83b79c2f4d7f445373e doc_id: 710664 cord_uid: u59v5v06 By March 2020, New York City became the early epicenter of the COVID-19 pandemic in the United States. Consequently, Columbia University, with its large portfolio of human subjects research, had to address the challenges of protecting thousands of research participants and research staff from potential exposure to COVID-19 while facilitating essential biomedical research, especially pandemic-related studies. The authors describe, from the perspective of Columbia’s research administration leadership, how the University and its primary teaching hospital ramped down—and later ramped up—human subjects research and reflect on lessons learned. As the pandemic unfolded, only studies offering the prospect of direct benefit to subjects were permitted to continue with in-person contact. New in-person participant enrollment ceased, except for COVID-19 prevention or treatment studies. Centralized, frequently updated communication about policies and procedures was disseminated to the Columbia research community. Procedural efficiencies were rapidly developed and implemented for review and oversight of human subjects research and contractual agreements for clinical trials. More frequent institutional review board meetings and 24-hour support markedly reduced turnaround time for COVID-19 studies, without delaying approvals of non–COVID-19 research. Research administration worked closely with relevant principal federal agencies, whose regulatory flexibility facilitated the efficient implementation of COVID-19–related research. Overall, the ramp-down and ramp-up of the majority of human subjects research, with specified priorities and accelerated processes, worked well. Adjustments were made to handle the increase in administrative tasks, the need to respond rapidly to added oversight responsibilities, and the management of the many new COVID-19–related research protocols. Timely, centralized communication, support for staff needs, prioritization, and collaboration were critical to successful research oversight at a large-scale academic setting in the midst of a pandemic. These perspectives may be useful to academic research centers addressing the current and future pandemics. As the pandemic unfolded, only studies offering the prospect of direct benefit to subjects were permitted to continue with in-person contact. New in-person participant enrollment ceased, except for COVID-19 prevention or treatment studies. Centralized, frequently updated communication about policies and procedures was disseminated to the Columbia research community. Procedural efficiencies were rapidly developed and implemented for review and oversight of human subjects research and contractual agreements for clinical trials. More frequent institutional review board meetings and 24-hour support markedly reduced turnaround time for COVID-19 studies, without delaying approvals of non-COVID-19 research. Research administration worked closely with relevant principal federal agencies, whose regulatory flexibility facilitated the efficient implementation of COVID-19-related research. Overall, the ramp-down and ramp-up of the majority of human subjects research, with specified priorities and accelerated processes, worked well. Adjustments were made to handle the increase in administrative tasks, the need to respond rapidly to added oversight responsibilities, and the management of the many new COVID-19-related research protocols. Timely, centralized communication, support for staff needs, prioritization, and collaboration were critical to successful research oversight at a large-scale academic setting in the midst of a pandemic. These perspectives may be useful to academic research centers addressing the current and future pandemics. New York City (NYC) was among the first places in the United States to experience cases of COVID-19, with the first case reported on February 29, 2020. By the first week of March, it appeared that NYC would become the early epicenter of the U.S. pandemic. As a result, NYC-based Columbia University, with a large portfolio of human subjects research, was faced with protecting thousands of research participants and research staff from potential exposure to COVID-19, while facilitating essential biomedical research on the virus. Other U.S. academic medical centers faced similar issues. 1 This article describes how the University and NewYork-Presbyterian Hospital (NYP) at Columbia University Irving Medical Center (CUIMC) ramped down-and later ramped up-human subjects research, as well as lessons learned. These insights may help researchers prepare for subsequent waves of COVID-19 or future pandemics. As the safety of participants and research staff was of paramount importance, Columbia acted quickly to minimize the risk of spreading COVID-19 between coworkers and between researchers and participants. Most importantly, on March 6, 2020, Columbia decided that only studies offering the prospect of direct benefit to subjects would be permitted to continue with in-person contact, and all new participant enrollment would be paused. At the same time, certain human studies relating to COVID-19 had to be launched or existing studies modified to add COVID-19 aims to contribute urgently needed data on the biology of the virus and COVID-19's prevention and treatment. 2, 3 Research administration at CUIMC determined that all human studies should be grouped into 1 of 4 categories: Studies permitted to continue: • Ongoing data analysis only As the pandemic raised many novel questions, all IRB-related researcher inquiries were directed to a central email inbox, where questions were answered by a few senior HRPO staff to maintain centralized and consistent advice. Rascal was also reprogrammed to identify ramp-down status, using "pause" or modify flags. The HRPO developed and administered the survey and reviewed initial responses within 3 days. Nearly all non-CUIMC Columbia human subjects studies had in-person procedures paused immediately on the assumption that most did not offer the prospect of direct benefit. Between March 15 and June 15, 2020, 45% of all IRB-approved human subject protocols were paused or modified to permit only remote procedures by the PI, 18% were required to pause in-person procedures by the IRB, and 36% had no IRB requirement to pause study procedures due to prospect of direct benefit, with 1% categorized as "other." To facilitate timely communication and better coordination of services, the Office of the EVPR transitioned its regular meetings of key unit heads from monthly to twice weekly. After the initial months of the pandemic, these meetings continued weekly. In addition, the EVPR Office, working with other university sponsors, was instrumental in creating a centralized COVID-19 Research Resources website with key information and detailed FAQs for the research community. As the COVID-19 website contained so much information, periodic communications were sent via a broad listserv to alert researchers when updates were added. Many of the studies permitted to continue required adjustments in procedures. The HRPO changed its processes to accommodate requests for COVID-19-related modifications, the increase in protocol filings for COVID-19 research, and the regular inflow of permitted studies not related to COVID-19. The HRPO's study management was made easier by the regulatory flexibility of the relevant federal agencies-the Department of Health and Human Services, including the National Institutes of Health, and the FDA-that quickly recognized the unprecedented public health emergency presented by the pandemic. [4] [5] [6] Several HRPO procedures were altered. All IRB meetings were held virtually. IRB rosters were revised to accommodate quorum needs and reviewers. Members of each of the 7 IRBs were added as alternate members of every IRB to expand the number of members who could potentially be available on a day's notice for a meeting. If a "regular" IRB member was not available for an ad hoc meeting or specific expertise was needed, HRPO staff quickly identified alternate members who were available and had the requisite expertise. During the COVID-19 crisis, PIs were permitted to submit protocols for prescreening by HRPO staff while full applications were being prepared, facilitating identification and rapid review of high-priority COVID-19 protocols. The HRPO waived the need for prospective IRB approval of modifications to comply with the ramp-down requirements, as permitted by federal regulations when a change is necessary to avoid an imminent hazard to participants. The IRBs continued to process non-COVID-19 protocols yet prioritized COVID-19-related research. IRBs met daily when necessary to conduct reviews no more than 24 hours after initial submission. Initially, one IRB was designated as a "rapid review" committee for emergent situations. However, this arrangement was soon replaced by weekly rotation of 5 IRBs to increase efficiency and avoid overwhelming a single committee. IRB minutes and feedback to PIs were completed by HRPO staff within 1 calendar day. For efficiency, HRPO staff revised consent forms themselves instead of requesting edits from research teams. Finally, IRB approval was issued as soon as the regulatory criteria were met, allowing minor changes to be made following approval. Using these tactics, Columbia IRBs processed more than 500 new COVID-19-related protocols between March 15 and October 15, 2020. In the initial 4 months, the IRBs held 77 meetings, of which 37 were added to accommodate COVID-19 research, a 92.5% increase from the pace before the pandemic. Despite the significantly increased volume, turnaround time for new protocol review and approval, including ancillary reviews (e.g., scientific, conflict of interest, biosafety), decreased dramatically from a prepandemic average of 40.9 days to only 8.8 days for COVID-19 protocols. Average turnaround time for non-COVID-19 protocols also decreased to 32.9 days (Figure 1 ). This modest, unanticipated effect may be attributed to the enhanced effort from IRB staff to promptly complete postreview administrative procedures. 7 Columbia's CTO provides support to investigators for contract and budget negotiation, subject recruitment, trial maintenance, research personnel training, and investigational new drug (IND) or investigational device exemption (IDE) assistance relating to industry-sponsored clinical trials. Once the pandemic began, many new COVID-19 trials and therapies required rapid review and contract negotiation. The FDA's willingness to review electronically submitted applications by email or telephone, rather than the usual paper forms, during off-hours and weekends usually permitted patient treatment within 24 to 48 hours after an emergency case was identified. Telephone calls with the FDA at 2 am on weekdays or on Saturday nights became the norm during the height of the pandemic. Once an application was approved by the FDA, Figure 1 Approval times of all new protocols from initial protocol submission to institutional review board approval during two 4-month periods of time, comparing pre-COVID-19 pandemic approvals to those during the pandemic, in calendar days. For the latter period, turnaround times were separated for COVID-19-related and non-COVID-19 protocols. The IAP also provided additional monitoring support for faculty IND sponsor-investigators during active trials to facilitate early review of research activities, such as review of regulatory files and documentation on informed consent, eligibility of participants, and safety of investigational products. The CTO provides an online tool called RecruitMe (https://recruit.cumc. columbia.edu), which permits potential volunteers to access Columbia clinical research studies of interest and request additional information. For researchers, RecruitMe provides a registry of potential participants for a particular study or future studies and allows researchers to track those contacted and enrolled. To highlight COVID-19 studies, RecruitMe staff quickly updated the site to include a readily visible link for study information and site modifications to enhance accessibility for COVID-19 searches. In April 2020, more than 5,000 inquiries specific to COVID-19 studies from potential participants were received, compared with the prepandemic monthly average of 2,000 inquiries for all studies. To support these inquiries, staff made themselves available around the clock to respond, support the posting of COVID-19 studies opening for recruitment, and train research teams in updating postings and managing their dashboards. By June 2020, New York State had issued guidelines regarding the phased restart of many of the activities shut down by COVID-19. Higher education research was in the first phase of reopening, and Columbia implemented extensive pandemic safety requirements to permit laboratory and clinical research to recommence, including gateway and ongoing testing, daily symptom checking, and facility modifications; these are beyond the scope of this article. Plans for restarting a research study required the approval of the PI's department or institute, which had overall responsibility for ensuring that research met reduced campus density and other safety requirements. Non-COVID-19 human subjects research was reintroduced in phases, with the highest priority given to existing clinical trials that offered the prospect of direct benefit and inpatient or emergency department clinical research. Enrollment of new subjects with in-person study procedures remained on hold; exceptions could be granted by the IRB. Three sequential phases reinitiated existing and new federally or foundationfunded research, industry-sponsored research, and research that did not offer direct benefit. Enrollment of participants was gradually expanded. As the ramp-up progressed, the HRPO reactivated protocols without specific PI requests when the risk/benefit ratio to participants was acceptable. The applicable department or institute was responsible for ensuring that all New York state and Columbia requirements were met. By September 1, 2020, all human subjects research that met required pandemic safety precautions had been reactivated at all Columbia campuses and IRB meetings returned to their usual biweekly schedules, although very highpriority COVID-19 vaccine or treatment trials continued to be given priority. The unprecedented COVID-19 crisis in NYC in early 2020 immersed health care and academic research institutions in crisis management overnight. In retrospect, as we navigated the continuing crisis, lessons were learned regarding human subjects research for a subsequent wave of COVID-19 or the next pandemic. In addition, some of the changes to regulatory oversight of human subjects research may bring postpandemic efficiencies to future research. 8 Centralized university-wide management of the COVID-19 crisis was key in fashioning a coherent response. This included the creation of specialized COVID-19 working groups (e.g., public health, research, campus life) across the university, as well as taking advantage of existing structures such as the EVPR Office. Columbia encouraged collaboration among university leaders to respond quickly to local, state, and federal requirements for pandemic response. Collaboration among the units of the EVPR Office and other senior administrators permitted changes in procedures to be made and communicated swiftly. Going forward, we will be looking at leveraging technology to ensure even better communication, for example, periodic distribution of brief videos covering key topics-an approach used by NYP leadership to communicate with its staff during the pandemic. We found at each point in the unfolding crisis that flexibility was key. Usual processes had to be revised, sometimes on a "let's just try this" basis, as the situation changed. The assistance of furloughed postdoctoral laboratory fellows, part of Columbia's redeployment of "nonessential" staff who were not permitted to be on campus and could not perform their usual responsibilities remotely, was invaluable to the HRPO, providing expertise in data management. The experience highlights the need to seek additional personnel resources from novel sources during times of crisis. Overall, our accelerated processes worked well. However, as we made adjustments to handle increased administrative tasks, the need to respond rapidly to added oversight responsibilities and the flood of new COVID-19 research, prioritization of pandemic-related studies, and tasks was critical. Given the tremendous workload of the IRBs during that time, in the future, we would suggest not requiring the detailed study-by-study inventory that we created at the beginning of the ramp-down. The survey process revealed great uncertainty as to what constituted "direct benefit" for participants, a subjective assessment that could vary over the course of a study. The benefits of this categorization may not have outweighed the burdens on HRPO staff and IRB chairs. To assist future prioritization in emergent situations, our electronic protocol submission process could be modified to include the selection of nonsubjective categories, for example, direct human contact and/or future on critical public health issues. During future public health emergencies, we would consider leaving the decision to pause or continue research to departmental or school administrators, based on University guidelines. The accelerated IRB review processes described here are not operationally sustainable given our large number of studies. Even a hypothetical doubling of IRB staff and faculty reviewers might not suffice to contend with the nonpandemic challenges of staff and faculty availability, study team responsiveness, single IRBs for multisite studies, and the processes for negotiating with other study sites and/or sponsors. Nonetheless, continued rapid review has been possible for a modest number of selected studies, for example, pandemic vaccine or intervention trials. All new COVID-19 protocols were initially prioritized equally by the HRPO, following prescreening, moving those that required convened review to an IRB meeting within 1-2 calendar days for the first several months, gradually loosening to within 1 week. We realized that a prescreening process that involved IRB chairs or members could identify studies that warranted immediate review and those that could wait for a regular IRB meeting. In the future, this process could be used for other urgent public health needs for research. The CTO prioritized the submission of INDs and IDEs to the FDA from the start because of the possible direct clinical impact of the investigational products. Implementing a system of prioritization clearly eased the burden on HRPO and CTO staff and focused their attention on the completion of the most time-sensitive tasks. Through the first 9 months of the pandemic, Columbia research administrators learned crucial lessons that may be helpful for other academic institutions facing a public health emergency. Key takeaways include the benefits of centralized administration for communication and coordination; the requirement for additional manpower to respond to administrative and regulatory pressures and to protect staff from burnout; and the value of prioritizing tasks, particularly for COVID-19 research. We suggest that it would be helpful for institutions similar to ours to develop training workshops for institutions planning for future public health emergencies, so that we may retain, rather than relearn, these lessons. Finally, what we accomplished could not have been done without the dedication of the staff and managers, who operated at a high level of professionalism under enormous pressure during a period of frightening health risks and to whom we express our deepest gratitude. Conducting clinical research in the era of Covid-19 Pandemic pandemonium: Pausing clinical research during the COVID-19 outbreak Opinion: A risk-benefit framework for human research during the COVID-19 pandemic Regulatory flexibility for COVID-19 research Office of Human Research Protections. OHRP Guidance on Coronavirus FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Public Health Emergency The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials The COVID-19 pandemic: A catalyst to improve clinical trials Acknowledgments: The authors acknowledge the efforts of faculty, staff, and trainees of Columbia University, NewYork-Presbyterian Hospital, and many study participants for their efforts to support human subjects research during the 2020 pandemic, especially studies related to COVID-19.Funding/Support: This work was supported by the National Institutes of Health grant 5UL1TR001873 (P.I. M. Reilly).Other disclosures: None reported.